SUPERNUS PHARMACEUTICALS, INC. (SUPN) Q3 2025 10-Q Quarterly Report
SUPERNUS PHARMACEUTICALS, INC. (SUPN) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 6, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
SUPERNUS PHARMACEUTICALS, INC. Q3 2025 10-Q Analysis
Management Discussion & Analysis
- • Revenue data and YoY comparison not provided in text
- • No profitability or margin figures disclosed in section
- • Best/worst performing product: ZURZUVAE with milestone payments up to $234M contingent on sales targets
- • Cash impact from Sage Acquisition including sale of marketable securities to fund $66.9M per share contingent payments
- • Near-term outlook includes contingent milestone payments through 2030 and potential Japan launch milestone by mid-2026
Risk Factors
- • New tariff risk due to recent US tariffs on pharmaceuticals, possibly increasing import and vendor costs, currently assessing financial impact
- • Legal risk materially updated: multiple litigation matters post-Sage acquisition, including securities class action, SEC subpoena, derivative litigation, and stockholder complaints in 2025
- • Regulatory risk from 2025 Executive Orders aiming to lower US pharmaceutical prices, potentially reducing revenue for commercial products
- • Market risk on ZURZUVAE commercialization: limited market acceptance risk due to boxed warning causing driving impairment, complicated reimbursement, and payer coverage restrictions
- • Financial risk related to dependency on collaboration with Biogen for ZURZUVAE commercialization success, with uncertain revenue timing and levels to support business goals
SUPERNUS PHARMACEUTICALS, INC. Q3 2025 Quarterly FinancialsXBRL
Revenue
$192M
▲ +9.3% YoY▲ +16.1% QoQ
Net Income
-$45M
▼ -217.2% YoY▼ -300.5% QoQ
Operating Margin
-31.4%
▼ -5460bp YoY▼ -3869bp QoQ
Net Margin
-23.5%
▼ -4540bp YoY▼ -3708bp QoQ
ROE
-4.3%
Total Assets
$1.4B
EPS (Diluted)
$-0.80
▼ -215.9% YoY▼ -300.0% QoQ
Operating Cash Flow
-$62M
▼ -215.2% YoY▼ -205.3% QoQ
Source: XBRL data from SUPERNUS PHARMACEUTICALS, INC. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on SUPERNUS PHARMACEUTICALS, INC.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.